KR20180043699A - Mischell emulsionized tocopherol composition and manufacturing method thereof - Google Patents
Mischell emulsionized tocopherol composition and manufacturing method thereof Download PDFInfo
- Publication number
- KR20180043699A KR20180043699A KR1020160136774A KR20160136774A KR20180043699A KR 20180043699 A KR20180043699 A KR 20180043699A KR 1020160136774 A KR1020160136774 A KR 1020160136774A KR 20160136774 A KR20160136774 A KR 20160136774A KR 20180043699 A KR20180043699 A KR 20180043699A
- Authority
- KR
- South Korea
- Prior art keywords
- tocopherol
- fatty acid
- weight
- parts
- acid ester
- Prior art date
Links
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 title claims abstract description 68
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 title claims abstract description 67
- 239000011732 tocopherol Substances 0.000 title claims abstract description 60
- 229930003799 tocopherol Natural products 0.000 title claims abstract description 59
- 239000000203 mixture Substances 0.000 title claims abstract description 57
- 229960001295 tocopherol Drugs 0.000 title claims abstract description 57
- 235000010384 tocopherol Nutrition 0.000 title claims abstract description 56
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 7
- 235000014113 dietary fatty acids Nutrition 0.000 claims abstract description 51
- 239000000194 fatty acid Substances 0.000 claims abstract description 51
- 229930195729 fatty acid Natural products 0.000 claims abstract description 51
- -1 glycerin fatty acid ester Chemical class 0.000 claims abstract description 39
- 239000000693 micelle Substances 0.000 claims abstract description 26
- 235000013305 food Nutrition 0.000 claims abstract description 21
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims abstract description 20
- 235000011187 glycerol Nutrition 0.000 claims abstract description 20
- 239000002537 cosmetic Substances 0.000 claims abstract description 7
- 150000004665 fatty acids Chemical class 0.000 claims description 14
- 235000019197 fats Nutrition 0.000 claims description 11
- 238000000034 method Methods 0.000 claims description 11
- 229920000223 polyglycerol Polymers 0.000 claims description 9
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 claims description 8
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 8
- 238000002156 mixing Methods 0.000 claims description 8
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 claims description 8
- 235000004835 α-tocopherol Nutrition 0.000 claims description 8
- 239000002076 α-tocopherol Substances 0.000 claims description 8
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 claims description 7
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 claims description 7
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 claims description 7
- 239000005642 Oleic acid Substances 0.000 claims description 7
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 claims description 7
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 claims description 7
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid group Chemical group C(CCCCCCC\C=C/CCCCCCCC)(=O)O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims description 7
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 claims description 6
- WGVKWNUPNGFDFJ-DQCZWYHMSA-N β-tocopherol Chemical compound OC1=CC(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C WGVKWNUPNGFDFJ-DQCZWYHMSA-N 0.000 claims description 6
- GZIFEOYASATJEH-VHFRWLAGSA-N δ-tocopherol Chemical compound OC1=CC(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1 GZIFEOYASATJEH-VHFRWLAGSA-N 0.000 claims description 6
- 235000021313 oleic acid Nutrition 0.000 claims description 5
- 239000005632 Capric acid (CAS 334-48-5) Substances 0.000 claims description 4
- 239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 claims description 4
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 claims description 4
- 235000020661 alpha-linolenic acid Nutrition 0.000 claims description 4
- 235000010389 delta-tocopherol Nutrition 0.000 claims description 4
- GPLRAVKSCUXZTP-UHFFFAOYSA-N diglycerol Chemical group OCC(O)COCC(O)CO GPLRAVKSCUXZTP-UHFFFAOYSA-N 0.000 claims description 4
- 235000010382 gamma-tocopherol Nutrition 0.000 claims description 4
- 229960004488 linolenic acid Drugs 0.000 claims description 4
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 claims description 4
- 229960002446 octanoic acid Drugs 0.000 claims description 4
- 235000007680 β-tocopherol Nutrition 0.000 claims description 4
- GZIFEOYASATJEH-UHFFFAOYSA-N D-delta tocopherol Natural products OC1=CC(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 GZIFEOYASATJEH-UHFFFAOYSA-N 0.000 claims description 3
- 238000001816 cooling Methods 0.000 claims description 3
- 229940105990 diglycerin Drugs 0.000 claims description 3
- 239000011590 β-tocopherol Substances 0.000 claims description 3
- 239000002478 γ-tocopherol Substances 0.000 claims description 3
- QUEDXNHFTDJVIY-DQCZWYHMSA-N γ-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1 QUEDXNHFTDJVIY-DQCZWYHMSA-N 0.000 claims description 3
- 239000002446 δ-tocopherol Substances 0.000 claims description 3
- 125000005313 fatty acid group Chemical group 0.000 claims 2
- 230000003647 oxidation Effects 0.000 abstract description 18
- 238000007254 oxidation reaction Methods 0.000 abstract description 18
- 230000003078 antioxidant effect Effects 0.000 abstract description 13
- 239000000839 emulsion Substances 0.000 abstract description 13
- 239000003963 antioxidant agent Substances 0.000 abstract description 9
- 238000010521 absorption reaction Methods 0.000 abstract description 7
- 238000003860 storage Methods 0.000 abstract description 5
- 230000001804 emulsifying effect Effects 0.000 abstract description 4
- 230000029087 digestion Effects 0.000 abstract description 3
- 235000013373 food additive Nutrition 0.000 abstract description 2
- 239000002778 food additive Substances 0.000 abstract description 2
- 230000007774 longterm Effects 0.000 abstract 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 12
- 239000003925 fat Substances 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 235000006708 antioxidants Nutrition 0.000 description 7
- 230000000052 comparative effect Effects 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 229960000984 tocofersolan Drugs 0.000 description 6
- 229930003427 Vitamin E Natural products 0.000 description 5
- 229940087168 alpha tocopherol Drugs 0.000 description 5
- 239000004973 liquid crystal related substance Substances 0.000 description 5
- 229910052757 nitrogen Inorganic materials 0.000 description 5
- 235000019165 vitamin E Nutrition 0.000 description 5
- 239000011709 vitamin E Substances 0.000 description 5
- 229940046009 vitamin E Drugs 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 4
- 238000004945 emulsification Methods 0.000 description 4
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 125000002640 tocopherol group Chemical class 0.000 description 3
- 235000019149 tocopherols Nutrition 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- 150000003722 vitamin derivatives Chemical class 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 208000000509 infertility Diseases 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 238000013112 stability test Methods 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 125000001020 α-tocopherol group Chemical group 0.000 description 2
- PZNPLUBHRSSFHT-RRHRGVEJSA-N 1-hexadecanoyl-2-octadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[C@@H](COP([O-])(=O)OCC[N+](C)(C)C)COC(=O)CCCCCCCCCCCCCCC PZNPLUBHRSSFHT-RRHRGVEJSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- AGNTUZCMJBTHOG-UHFFFAOYSA-N 3-[3-(2,3-dihydroxypropoxy)-2-hydroxypropoxy]propane-1,2-diol Chemical compound OCC(O)COCC(O)COCC(O)CO AGNTUZCMJBTHOG-UHFFFAOYSA-N 0.000 description 1
- WOKDXPHSIQRTJF-UHFFFAOYSA-N 3-[3-[3-[3-[3-[3-[3-[3-[3-(2,3-dihydroxypropoxy)-2-hydroxypropoxy]-2-hydroxypropoxy]-2-hydroxypropoxy]-2-hydroxypropoxy]-2-hydroxypropoxy]-2-hydroxypropoxy]-2-hydroxypropoxy]-2-hydroxypropoxy]propane-1,2-diol Chemical compound OCC(O)COCC(O)COCC(O)COCC(O)COCC(O)COCC(O)COCC(O)COCC(O)COCC(O)COCC(O)CO WOKDXPHSIQRTJF-UHFFFAOYSA-N 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 229920000877 Melamine resin Polymers 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 241000209140 Triticum Species 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 238000005273 aeration Methods 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 238000003915 air pollution Methods 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000000149 argon plasma sintering Methods 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229940066595 beta tocopherol Drugs 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 238000004581 coalescence Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- HHEAADYXPMHMCT-UHFFFAOYSA-N dpph Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1[N]N(C=1C=CC=CC=1)C1=CC=CC=C1 HHEAADYXPMHMCT-UHFFFAOYSA-N 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000005189 flocculation Methods 0.000 description 1
- 230000016615 flocculation Effects 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 231100000535 infertility Toxicity 0.000 description 1
- 210000004020 intracellular membrane Anatomy 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 150000004667 medium chain fatty acids Chemical class 0.000 description 1
- JDSHMPZPIAZGSV-UHFFFAOYSA-N melamine Chemical compound NC1=NC(N)=NC(N)=N1 JDSHMPZPIAZGSV-UHFFFAOYSA-N 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000008347 soybean phospholipid Substances 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- JYKSTGLAIMQDRA-UHFFFAOYSA-N tetraglycerol Chemical compound OCC(O)CO.OCC(O)CO.OCC(O)CO.OCC(O)CO JYKSTGLAIMQDRA-UHFFFAOYSA-N 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- 150000003781 β-tocopherols Chemical class 0.000 description 1
- 150000003785 γ-tocopherols Chemical class 0.000 description 1
- 150000003789 δ-tocopherols Chemical class 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/03—Organic compounds
- A23L29/035—Organic compounds containing oxygen as heteroatom
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/116—Heterocyclic compounds
- A23K20/121—Heterocyclic compounds containing oxygen or sulfur as hetero atom
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/158—Fatty acids; Fats; Products containing oils or fats
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
- A23P10/00—Shaping or working of foodstuffs characterised by the products
- A23P10/30—Encapsulation of particles, e.g. foodstuff additives
- A23P10/35—Encapsulation of particles, e.g. foodstuff additives with oils, lipids, monoglycerides or diglycerides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/14—Liposomes; Vesicles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/678—Tocopherol, i.e. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/70—Vitamins
- A23V2250/712—Vitamin E
Abstract
Description
본 발명은 마이셀 유화기술을 사용하여 토코페롤을 유화하는 조성물 및 그 제조 방법에 관한 것으로, 더욱 상세하게는 천연토코페롤을 마이셀 내에 봉입시켜 산화를 방지하고, 보존 안정성 및 분산성을 증가시켜 흡수 속도를 증가시키며, 식품, 화장품, 사료 등에 용이하게 첨가할 수 있도록 한 마이셀 유화 토코페롤 조성물 및 그 제조 방법에 관한 것이다.The present invention relates to a composition for emulsifying tocopherol using micellar emulsification technology and a method for preparing the same, more particularly, to a composition for preventing the oxidation of natural tocopherol in micelles, increasing storage stability and dispersibility, And to be easily added to foods, cosmetics, feeds and the like, and to a process for producing the tocopherol composition.
일반적으로 토코페롤은 비타민 E로 불리며, 지용성 성분으로 지방질과 함께 분포되어 있다. 식품에서는 천연 항산화제로서 식품의 산화를 방지하는 것으로 널리 알려져 있으며, 생체에서는 토코페롤이 순환계 질환과 암의 예방, 노화와 퇴행성 질환의 예방, 항불임 등에 생리학적인 기능과 영양학적인 활성을 함께 지니고 있는 것으로 보고된 바 있으며, α-토코페롤의 정기적인 복용은 동맥경화의 진행을 억제하고, 백내장을 예방하는 효과가 있음이 알려져 있다. 생체 내에서 혈중 콜레스테롤 함량은 토코페롤의 복용으로 인하여 그 수치를 저하시켜주며, 상처의 치유를 촉진시켜줄 뿐만 아니라, 화상의 흉터 치료에도 탁월한 효과가 있는 것으로 보고되고 있다. 또한, 대기오염으로부터의 호흡기점막을 보호하며, 해독 작용, 세포내막의 유지보호기능, 피부습진, 부종, 혈액의 병변 개선, 면역기능 증진 등의 각종 생리적 효능을 지니고 있다. 그러나, 생체 내에서는 토코페롤을 직접 합성할 수 없기 때문에 음식물 또는 식품으로부터 섭취 하여야만 한다. 또한, 우리 신체는 수분함량이 약 70% 정도 함유되어 있는 수상임으로 유지 용해성인 토코페롤의 이용 효과는 매우 감소되므로 그 효과를 극대화하기 위해서는 토코페롤의 수용성 증대 조성물의 개발과 이를 함유하는 가공식품의 개발이 절실히 필요한 실정이다. 현재까지 토코페롤에 관련한 연구로는 많은 연구자들에 의하여 유지용해성을 갖는 토코페롤이 생체 내에서의 작용기작 뿐만 아니라, 식품에서의 항산화성 등에 대한 수많은 연구가 이루어졌으며, 현재도 많은 연구가 진행 중에 있다. 하지만, 토코페롤이 갖는 유지용해성을 수용성화 하려는 연구는 식품 분야에서는 아주 미비하다.In general, tocopherol is called vitamin E and is a fat-soluble ingredient distributed along with the fat. As a natural antioxidant in foods, it is widely known to prevent the oxidation of food. In living organisms, tocopherol has physiological functions and nutritional activities such as prevention of circulatory diseases and cancer, prevention of aging and degenerative diseases, and anti- It has been reported that periodic administration of alpha -tocopherol inhibits progression of arteriosclerosis and prevents cataracts. The blood cholesterol content in vivo has been reported to decrease the level of tocopherol, and not only promote wound healing, but also has an excellent effect on scar treatment of burns. In addition, it protects the respiratory mucous membrane from air pollution and has various physiological effects such as detoxifying action, preservation function of intracellular membrane, skin eczema, edema, improvement of blood lesion, and improvement of immune function. However, since it is impossible to directly synthesize tocopherol in vivo, it must be ingested from food or food. In order to maximize the effect of tocopherol, the water soluble component of tocopherol is added to the body, the water content of the body is about 70% It is an urgent necessity. To date, many studies on tocopherol have been carried out by many researchers, and many studies have been conducted on tocopherol, which is a soluble and soluble compound, in not only the action mechanism in vivo but also the antioxidant properties in food. However, studies on the water solubility of tocopherol have not been found in the field of food.
지용성 성분의 체내 안정성 향상을 위한 종래의 기술로는, 전분, 알긴산, 멜라민, 에칠셀룰로스, 키토산 등을 벽재로 사용하여 눈에 보일 만큼의 거대캡슐이나 20μm 이상의 미세캡슐을 제조하거나, 기능성 물질을 베이스 처방 내에서 필요 이상으로 고농도 처방하여 유통기간 내 손실분을 감안하거나, 하이루론산, 비타민C 등과 같은 안정화제나 항산화제, 첨가제 등을 고농도로 배합하거나 또는 영양성분의 흡수전달이 용이하도록 리포좀, 실리콘 등의 코팅제를 다량으로 배합하는 방법을 사용하였다. 그러나, 종래의 방법은 기능성 물질이나 첨가된 안정제, 코팅제, 항산화제 등이 원료 자체의 안정도는 일정하다고 할 수 있으나, 일단 식품, 의약품 등의 제형에 첨가되면 시간의 경과 및 가혹조건에 따른 색상, 점도, pH 등의 물성의 경시변화가 심하게 나타나는 문제점이 있어 상품 자체에 이상을 초래하게 되는 문제점이 야기된다.Conventional techniques for improving the body stability of fat-soluble ingredients include preparing macroscopic capsules or macroscopic capsules that are visible to the naked eye using starch, alginic acid, melamine, ethylcellulose, chitosan, It is also possible to prescribe a higher concentration than necessary in the prescription and to take into consideration the loss in the distribution period, or to add a stabilizer, antioxidant, and additives such as hydrulonic acid and vitamin C at a high concentration, A method of blending a large amount of a coating agent was used. However, in the conventional method, the stability of the raw material itself can be said to be constant with the functional material, the added stabilizer, the coating agent, the antioxidant and the like. However, once added to the formulations of foods, medicines, There is a problem that the physical properties such as viscosity, pH and the like change with time, which causes problems in the product itself.
한편, 액정은 분자간의 규칙적인 배향에 의하여 액상보다 상대적으로 적은 분자 운동성을 가지며, 이로 인해점도 및 유동성 면에서는 액체처럼 행동하나, 빛의 산란과 반사 같은 물성에 있어서는 결정성의 물성을 나타내는 등 독특한 성질을 가지고 있다. 이와 같은 상대적으로 적은 분자간 분자 운동성으로 인하여, 액정은 화장품, 의약품 등의 분야에서 불안정한 물질의 안정성을 향상시키는 특성을 나타낸다.On the other hand, liquid crystals behave like liquids in terms of viscosity and fluidity due to their relatively lower molecular mobility than liquid phases due to regular alignment between molecules, but they have unique properties such as crystalline properties in light scattering and reflection properties Lt; / RTI > Due to such relatively small intermolecular mobility, liquid crystals exhibit the property of improving the stability of unstable materials in the field of cosmetics, medicines and the like.
이러한 액정 유화의 가장 큰 특징은 라멜라 구조막을 가지고 있어 보습 유지력이 일반 유화에 비해 뛰어나다는 것이다. 또한, 액정 유화를 실시할 경우 종래의 유상/수상, 수상/유상 유화에 비해 현저히 높은 생리활성물질 안정화 동시에 생리활성물질의 서방성을 동시에 만족시키는 이점이 있다. 그러나, 산화에 불안정한 물질인 천연토코페롤을 안정한 형태로 미세마이셀에 봉입한 조성물은 없었다.The most important feature of such liquid crystal emulsification is that it has a lamellar structure film, which is superior in moisture retention to general emulsification. In addition, when the liquid crystal emulsification is carried out, there is an advantage that both the stabilization of the physiologically active substance which is significantly higher than that of the conventional oil phase / water phase and water / oil phase emulsion and simultaneously the sustained release of the physiologically active substance are satisfied. However, there was no composition in which natural tocopherol, which is a substance unstable to oxidation, was enclosed in micro-micelles in a stable form.
따라서, 본 발명의 발명자들은 지용성의 토코페롤이 갖고 있는 많은 생리활성 기능을 수용액 상태에서도 발현할 수 있도록 유지 용해성을 가지며 흡수가 향상된 마이셀 유화 토코페롤 조성물을 개발하고자 하였다. Accordingly, the inventors of the present invention have developed a micelle-emulsifying tocopherol composition having improved solubility and improved absorption so that many physiologically active functions of fat-soluble tocopherol can be expressed even in an aqueous solution state.
상기와 같은 종래 기술의 문제점을 해결하기 위하여, 본 발명에서 해결하고자 하는 과제는 산화 및 극성의 변화가 심하여 불안정한 천연토코페롤을 안정화시켜 기능성을 향상하고, 식품에 첨가시 분산성을 증대시키고, 흡수 속도를 증대할 수 있는 초미세사이즈의 마이셀 유화 토코페롤 조성물 및 그 제조 방법을 제공하고자 하는 것이다.In order to solve the problems of the prior art as described above, a problem to be solved by the present invention is to stabilize unstable natural tocopherol by a large change in oxidation and polarity, to improve functionality, to increase dispersibility upon addition to food, And to provide a method for producing the micelle-tocopherol composition.
상기와 같은 과제를 해결하기 위하여, 본 발명은 (a) 천연토코페롤 1 내지 90 중량부; (b) 중쇄 지방산을 함유하는 유지 10 내지 99 중량부; (c) 글리세린지방산에스테르 1 내지 20 중량부; 및 (d) 폴리글리세린지방산에스테르 1 내지 30 중량부를 포함하는 마이셀 유화 토코페롤 조성물을 제공한다.In order to solve the above problems, the present invention provides a composition comprising (a) 1 to 90 parts by weight of natural tocopherol; (b) 10 to 99 parts by weight of a fat-containing fatty acid chain; (c) 1 to 20 parts by weight of a glycerin fatty acid ester; And (d) 1 to 30 parts by weight of a polyglycerol fatty acid ester.
상기 천연토코페롤은 알파-, 베타-, 감마- 및 델타-토코페롤로 이루어지는 군으로부터 선택되는 것이 바람직하다.Preferably, the natural tocopherols are selected from the group consisting of alpha-, beta-, gamma- and delta-tocopherol.
상기 중쇄 지방산은 카프릴산, 카프릭산 및 이들의 혼합물을 90중량% 이상 포함하는 것이 바람직하다.Preferably, the heavy chain fatty acid comprises at least 90% by weight of caprylic acid, capric acid and mixtures thereof.
상기 글리세린지방산에스테르 및 폴리글리세린지방산에스테르를 구성하는 지방산은 올레인산, 리놀산, 리놀렌산 및 이들의 혼합물로 이루어지는 군으로부터 선택되는 것이 바람직하다.The fatty acid constituting the glycerin fatty acid ester and the polyglycerin fatty acid ester is preferably selected from the group consisting of oleic acid, linoleic acid, linolenic acid, and mixtures thereof.
상기 폴리글리세린지방산에스테르를 구성하는 폴리글리세린은 디글리세린, 트리글리세린, 테트라글리세린, 펜타글리세린, 헥사글리세린, 데카글리세린 및 이들의 혼합물로 이루어지는 군으로부터 선택되는 것이 바람직하다.The polyglycerin constituting the polyglycerin fatty acid ester is preferably selected from the group consisting of diglycerin, triglycerin, tetraglycerin, pentaglycerin, hexaglycerin, decaglycerin and mixtures thereof.
상기 마이셀의 직경은 0.1~500μm인 것이 바람직하다.The diameter of the micelle is preferably 0.1 to 500 탆.
상기 조성물은 식품, 화장품 또는 사료에 사용하는 것이 바람직하다.The composition is preferably used in food, cosmetics or feed.
또한, 본 발명은 (1) (a) 천연토코페롤 10 내지 90 중량부, (b) 중쇄 지방산을 함유하는 유지 10 내지 90 중량부, (c) 글리세린지방산에스테르 1 내지 20 중량부를 35 내지 40℃에서 혼합하고, 질소를 투입하면서 5 내지 10분 동안 2,000 내지 3,000 rpm으로 호모믹싱하는 단계; (2) 상기 단계 (1)에서 호모믹싱된 혼합물을 초고압호모게나이져에 통과시키는 단계; 및 (3) 상기 단계 (2)에서 초고압호모게나이져에 통과된 혼합물에 폴리글리세린지방산에스테르 1 내지 30 중량부를 첨가하여 혼합하고, 3 내지 5분 동안 호모믹싱 후 30℃ 이하로 냉각시키는 단계를 포함하는 마이셀 유화 토코페롤 조성물의 제조방법을 제공한다.(B) 10 to 90 parts by weight of a fat-containing fatty acid-containing fat; (c) 1 to 20 parts by weight of a glycerin fatty acid ester at 35 to 40 占 폚; Mixing and homomixing at 2,000 to 3,000 rpm for 5 to 10 minutes while introducing nitrogen; (2) passing the homomixed mixture through an ultrahigh pressure homogenizer in step (1); And (3) adding 1 to 30 parts by weight of polyglycerol fatty acid ester to the mixture passed through the ultra-high pressure homogenizer in the step (2), mixing the mixture for 3 to 5 minutes and then cooling the mixture to 30 ° C or less The present invention provides a method for producing a micellar emulsified tocopherol composition.
본 발명의 제조 방법으로 제조되는 마이셀 유화 토코페롤 조성물은 천연토코페롤이 미세 마이셀 내에 봉입되어, 항산화제의 문제인 보관시의 산화안정성이 확보됨으로써 장기 저장이 가능하고, 취급이 용이하다. 또한, 분산성이 증대되어 항산화 목적으로 식품에 첨가 시 추가하는 식품첨가물이 필요 없고, 다른 성분과의 혼합이 용이하며, 섭취 시 체내에서 보다 잘 분산되어 흡수 속도를 증가시킬 수 있으므로, 식품, 화장품 및 사료 산업상 매우 유용한 것이다.The micellar emulsifying tocopherol composition prepared by the method of the present invention can be stored for a long period of time and is easy to handle since the natural tocopherol is enclosed in the micro-micelles and oxidation stability during storage, which is a problem of the antioxidant, is secured. In addition, since the dispersibility is increased, the food additive added to the food for the purpose of antioxidation is not needed, and it can be easily mixed with the other ingredients and can be more easily dispersed in the body at the time of ingestion, And is very useful in the feed industry.
도 1은 본 발명의 실시예로부터 제조된 조성물의 터비스캔을 이용한 유화 안정성 실험 결과를 나타낸 것이다.
도 2는 본 발명의 비교예로부터 제조된 조성물의 터비스캔을 이용한 유화 안정성 실험 결과를 나타낸 것이다.FIG. 1 shows emulsion stability test results of a composition prepared from an embodiment of the present invention using a turboscan.
2 shows the emulsion stability test results of the composition prepared from the comparative example of the present invention using a turbine scan.
이하, 본 발명을 상세하게 설명한다.Hereinafter, the present invention will be described in detail.
본 발명의 발명자들은 천연토코페롤을 사용함에 있어, 산화안정성을 확보하고, 식품에 첨가시 분산성을 증대시키고 흡수 속도를 증대 하기 위해 예의 연구한 결과, 천연토코페롤을 함유하는 유지를 마이셀에 봉입시켜 유화한 경우, 상대적으로 적은 분자간 분자 운동성으로 인하여, 천연토코페롤의 안정성 및 분산성이 향상됨을 확인하고, 이를 토대로 본 발명을 완성하기에 이르렀다.The inventors of the present invention have conducted intensive studies in order to secure the oxidation stability in natural tocopherol and to increase the dispersibility and the absorption rate when added to foods. As a result, it has been found that the oil containing natural tocopherol is enclosed in micelles, It has been confirmed that the stability and dispersibility of natural tocopherol are improved due to the relatively low intermolecular mobility, and the present invention has been accomplished on the basis thereof.
따라서, 본 발명은 (a) 천연토코페롤 1 내지 90 중량부; (b) 중쇄 지방산을 함유하는 유지 10 내지 99 중량부; (c) 글리세린지방산에스테르 1 내지 20 중량부; 및 (d) 폴리글리세린지방산에스테르 1 내지 30 중량부를 포함하는 마이셀 유화 토코페롤 조성물을 제공한다.Accordingly, the present invention provides a composition comprising: (a) 1 to 90 parts by weight of natural tocopherol; (b) 10 to 99 parts by weight of a fat-containing fatty acid chain; (c) 1 to 20 parts by weight of a glycerin fatty acid ester; And (d) 1 to 30 parts by weight of a polyglycerol fatty acid ester.
토코페롤은 항불임효과를 갖는 지용성 비타민 E의 유도체의 일군으로 담황~황색의 점조한 액체이며, 비타민 E로도 명명된다. α-, β-, γ- 및 δ-토코페롤이 천연에 존재하며, 가장 흔하고 생체 활성이 큰 것은 α-토코페롤인데 비타민 E의 대명사처럼 사용된다. 비타민 E는 동물의 항(抗) 불임인자(antisterility vitamin)로서 발견되었으며, 생체에서의 중요한 기능은 항(抗)산화제로서 세포 내에서 산화되기 쉬운 물질, 특히 세포막을 구성하고 있는 불포화 지방산의 산화를 억제함으로써 세포막의 손상과 나아가서 조직의 손상을 막아준다. 1일 소요량은 성인은 10~15mg. 소맥과 쌀의 배자유에 특히 많지만 동물성 유지에는 거의 존재하지 않는다. 결핍증은 적혈구 용혈 항진증, 빈혈, 불임 등이다. 식품의 산화방지 효과는 α-가 가장 크고, 이하 β-(α-의 33%), γ-, δ-의 순이고, 일반적으로 유지성 식품의 산화방지에 쓰이지만 산화방지력은 그리 강하지 않다. 사용조건에 따라 효과가 변동된다. 상기 천연토코페롤은 알파-토코페롤, 베타-토코페롤, 감마-토코페롤 및 델타-토코페롤로 이루어지는 군으로부터 선택되는 것이 바람직하다. 천연토코페롤의 함량은 1 내지 90중량부인 것이 바람직한데, 그 함량이 1중량부 미만이면, 첨가에 따른 효과가 미미하며, 90중량부를 초과하는 경우, 초과 투입에 따른 상승효과가 적어 경제적이지 못하다. Tocopherol is a group of derivatives of fat-soluble vitamin E that has anti-infertility effect, and is a viscous-yellow viscous liquid, also called vitamin E. α-, β-, γ-, and δ-tocopherols exist naturally, and the most common and the most bioactive is α-tocopherol, which is used as a synonym for vitamin E. Vitamin E has been found as an antiserum vitamin in animals. An important function in living organisms is the oxidation of unsaturated fatty acids, which constitute cell membranes, as anti-oxidants, Inhibits cell membrane damage and prevents tissue damage. The daily requirement is 10 ~ 15mg for adults. It is especially abundant in the freezing of wheat and rice, but rarely in animal fats. Deficiency is red blood cell hemolysis, anemia, and infertility. The antioxidant effect of food is the highest in α-, followed by β- (33% of α-), γ-, and δ-, and generally used to prevent oxidation of persistent foods, but the antioxidant power is not so strong. The effect varies depending on the conditions of use. The natural tocopherols are preferably selected from the group consisting of alpha-tocopherol, beta-tocopherol, gamma-tocopherol and delta-tocopherol. The content of natural tocopherol is preferably 1 to 90 parts by weight. If the content is less than 1 part by weight, the effect of addition is insignificant. If the content is more than 90 parts by weight, synergistic effect is not obtained due to excess input.
상기 중쇄 지방산은 카프릴산, 카프릭산 및 이들의 혼합물일 수 있으며, 그 함량은 90중량% 이상 포함하는 것이 바람직하다.The heavy chain fatty acid may be caprylic acid, capric acid, or a mixture thereof, and the content thereof is preferably 90 wt% or more.
상기 글리세린지방산에스테르는 올레인산, 리놀산, 리놀레산 및 이들의 혼합물로 이루어진 군으로부터 선택된 것을 사용하는 것이 바람직하며, 올레인산 (oleic acid)이 80% 이상 함유된 것을 사용하는 것이 산화 안정성 및 소화흡수면에서 가장 바람직하다. 이때, 올레인 지방산을 함유하는 글리세린지방산에스테르는 1차 마이셀을 형성하는 기재로 작용한다. 글리세린지방산에스테르의 함량은 1 내지 20중량부인 것이 바람직한데, 그 함량이 1중량부 미만이면, 첨가에 따른 마이셀 형성효과가 미미하며, 20중량부를 초과하는 경우, 초과투입에 따른 상승효과가 적어 경제적이지 못하다.The glycerin fatty acid ester is preferably selected from the group consisting of oleic acid, linoleic acid, linoleic acid, and mixtures thereof. It is most preferable that the glycerin fatty acid ester contains oleic acid in an amount of 80% or more in terms of oxidation stability and digestion and absorption Do. At this time, the glycerin fatty acid ester containing oleic acid serves as a base for forming the primary micelle. The content of the glycerin fatty acid ester is preferably 1 to 20 parts by weight. If the content of the glycerin fatty acid ester is less than 1 part by weight, the effect of forming the micelle upon addition is insignificant. If it exceeds 20 parts by weight, I can not.
상기 폴리글리세린지방산에스테르는 1차 마이셀 형성제인 글리세린지방산에스테르와 함께 2차 마이셀 형성제의 역할을 하며, 강력한 마이셀을 형성하여 천연토코페롤을 외부와 차단하여 안정성을 극대화하며, 친수성을 극대하여 분산성을 좋게 하여 사용성을 넓혀준다. 이때 구성 지방산이 올레인산, 리놀산, 리놀렌산 및 이들의 혼합물로 이루어진 군으로부터 선택된 지방산으로 제조한 폴리글리세린지방산이며, 폴리글리세린은 디글리세린, 트리글리세린, 테트라글리세린, 펜타글리세린, 헥사글리세린, 데카글리세린 및 이들의 혼합물로 이루어진 군으로 선택된 것이 바람직하다. 폴리글리세린지방산에스테르의 함량은 1 내지 30중량부인 것이 바람직한데, 폴리글리세린지방산에스테르의 함량이 1중량부 미만이면, 마이셀 형성이 어렵고 수분산성이 떨어지며, 30중랑부를 초과하면 추가에 따른 효과가 없어 경제적이지 못하다.The polyglycerin fatty acid ester acts as a secondary micelle forming agent together with a glycerin fatty acid ester which is a primary micelle forming agent and forms strong micelles to block natural tocopherol from the outside to maximize stability and to disperse hydrophilicity extremely It improves usability by making it good. Wherein the constituent fatty acid is a polyglycerin fatty acid prepared from a fatty acid selected from the group consisting of oleic acid, linoleic acid, linolenic acid, and mixtures thereof, and the polyglycerin is selected from the group consisting of diglycerin, triglycerin, tetraglycerin, pentaglycerin, hexaglycerin, decaglycerin, And mixtures thereof. When the content of the polyglycerol fatty acid ester is less than 1 part by weight, it is difficult to form micelles and the water dispersibility is poor. When the content of the polyglycerol fatty acid ester is more than 30 parts by weight, I can not.
본 발명의 조성물 중의 천연토코페롤은 마이셀 형성제에 의해 안정적으로 형성된 유화제막 내부에 내포된다. 이러한 마이셀은 외부의 자극과의 직접 접촉을 막아 주기 때문에 산화에 약한 토코페롤이 보호되고, 수분산성이 증대되어 다른 식품에 첨가 시 혼합이 용이하며, 체내에서 보다 잘 분산되어 흡수성이 증가된다. 또한, 마이셀의 상대적으로 적은 분자간 분자 운동성으로 인하여, 안정성이 향상된다.The natural tocopherol in the composition of the present invention is contained inside the emulsifier film stably formed by the micelle forming agent. Because these micelles prevent direct contact with external stimuli, they protect tocopherol, which is weak to oxidation, and increase water dispersibility, which facilitates mixing when added to other foods and improves water absorption in the body. In addition, stability is improved due to the relatively small intermolecular mobility of the micelle.
이러한 마이셀 내에 봉입된 토코페롤 조성물의 직경은 0.1 내지 500μm의 미세사이즈를 갖는 것이 바람직하다. 직경이 0.1μm 미만이면, 크기가 상대적으로 작아짐에 따라 소화흡수면에서 바람직하나, 액정형성 시간이 길어지고, 500μm를 초과하면, 지방구의 합일이 일어날 가능성이 커지고, 소화흡수 시간이 길어지므로 바람직하지 않다.The diameter of the tocopherol composition sealed in the micelle is preferably in the range of 0.1 to 500 mu m. When the diameter is less than 0.1 탆, the liquid crystal forming time is long, while the size is relatively small. However, when the diameter is more than 500 탆, the possibility of lipid shedding increases and the digestion absorption time becomes longer not.
본 발명에 따른 마이셀 유화 토코페롤 조성물의 제조방법은 (1) (a) 천연토코페롤 10 내지 90 중량부, (b) 중쇄 지방산을 함유하는 유지 10 내지 90 중량부, (c) 글리세린지방산에스테르 1 내지 20 중량부를 35 내지 40℃에서 혼합하고, 질소를 투입하면서 5 내지 10분 동안 2,000 내지 3,000 rpm으로 호모믹싱하는 단계; (2) 상기 단계 (1)에서 호모믹싱된 혼합물을 초고압호모게나이져에 통과시키는 단계; 및 (3) 상기 단계 (2)에서 초고압호모게나이져에 통과된 혼합물에 폴리글리세린지방산에스테르 1 내지 30 중량부를 첨가하여 혼합하고, 3 내지 5분 동안 호모믹싱 후 30℃ 이하로 냉각시키는 단계를 포함하는 것을 특징으로 한다.(A) 10 to 90 parts by weight of natural tocopherol; (b) 10 to 90 parts by weight of a fat-containing fatty acid; (c) glycerin fatty acid ester 1 to 20 Mixing the parts by weight at 35 to 40 占 폚 and homomixing at 2,000 to 3,000 rpm for 5 to 10 minutes while introducing nitrogen; (2) passing the homomixed mixture through an ultrahigh pressure homogenizer in step (1); And (3) adding 1 to 30 parts by weight of polyglycerol fatty acid ester to the mixture passed through the ultra-high pressure homogenizer in the step (2), mixing the mixture for 3 to 5 minutes and then cooling the mixture to 30 ° C or less .
상기 제조 방법을 각 단계별로 상세히 설명한다.The above manufacturing method will be described in detail for each step.
먼저, (a) 천연토코페롤 1 내지 90중량부, (b) 카프릴산, 카프릭산 및 이들의 혼합물로 이루어진 군으로부터 선택된 중쇄지방산을 함유하는 유지 10 내지 99 중량부, (c) 글리세린지방산에스테르 1 내지 20 중량부를 35 내지 40℃에서 혼합하고, 질소를 투입하면서 5 내지 10분 동안 2,000 내지 3,000rpm으로 호모믹싱한다. 이때 가온 온도가 35℃ 미만이면 혼합이 균일하게 안 되고, 점도의 영향으로 토코페롤과 글리세린지방산에스테르 간의 마이셀의 형성이 어려워지는 문제점이 있고, 40℃를 초과하면 천연토코페롤의 산화가 진행되는 문제가 발생하므로 바람직하지 못하다. 이때, 호모믹싱하는 회전속도는 2,000 내지 3,000rpm인 것이 바람직하며, 그 회전속도가 2,000rpm 이하일 경우, 마이셀의 형태가 불균일하게 되는 문제점이 있을 수 있으며, 3,000rpm을 초과하는 경우 마이셀의 직경이 너무 작아져 원료 물질이 충분히 마이셀 내부에 봉입되지 않을 수 있다.First, 10 to 99 parts by weight of a fat-containing fatty acid selected from the group consisting of (a) 1 to 90 parts by weight of natural tocopherol, (b) caprylic acid, capric acid and mixtures thereof, (c) glycerin fatty acid ester 1 to 20 parts by weight are mixed at 35 to 40 占 폚 and homomixed at 2,000 to 3,000 rpm for 5 to 10 minutes while introducing nitrogen. If the heating temperature is lower than 35 ° C, the mixing is not uniform, and the formation of micelles between tocopherol and glycerin fatty acid esters becomes difficult due to the influence of the viscosity. When the temperature exceeds 40 ° C, oxidation of natural tocopherol occurs Which is undesirable. At this time, it is preferable that the homomixing rotational speed is 2,000 to 3,000 rpm, and when the rotational speed is 2,000 rpm or less, the shape of the micelles may be uneven. If the rotational speed is 3,000 rpm or more, The raw material may not be sufficiently enclosed in the micelle.
그 다음, 상기 단계에서 호모믹싱된 혼합물을 고압호모게나이저에 통과시킨다. 호모믹싱된 혼합물은 고압호모게나이저를 통과하면서 입자의 사이즈가 미세사이즈로 작아지며, 양친매성인 글리세린지방산에스테르의 친유성 부분이 천연토코페롤의 계면에 마이셀을 형성하기 쉬워진다. 바람직한 구체예로서, 상기 고압호모게나이저의 압력은 10,000 내지 18,000psi일 수 있다. The homomixed mixture is then passed through a high pressure homogenizer in this step. The homomixed mixture passes through a high pressure homogenizer and the size of the particles is reduced to a fine size and the lipophilic portion of the amphipathic glycerin fatty acid ester tends to form micelles at the interface of natural tocopherol. In a preferred embodiment, the pressure of the high pressure homogenizer may be between 10,000 and 18,000 psi.
마지막으로, 마이셀 형성제인 폴리글리세린지방산에스테르 1 내지 30중량부를 첨가하여 혼합하고, 3 내지 5분 동안 호모믹싱 후 30℃이하로 냉각시킨다. 이때, 폴리글리세린지방산에스테르의 친유성기와 글리세린지방산에스테르의 친유성기는 서로 회합하여 안정한 마이셀을 형성하게 된다. 상기 폴리글리세린지방산에스테르의 지방산은 올레인산, 리놀산, 리놀렌산 및 이들의 혼합물로 이루어진 군으로부터 선택된 것이 바람직하다. 또한, 폴리글리세린은 디글리세린, 트리글리세린, 테트라글리세린, 펜타글리세린, 헥사글리세린, 데카글리세린 및 이들의 혼합물일 수 있다.Finally, 1 to 30 parts by weight of a polyglycerin fatty acid ester as a micelle forming agent is added and mixed, and after homomixing for 3 to 5 minutes, the mixture is cooled to 30 캜 or lower. At this time, the lipophilic group of the polyglycerin fatty acid ester and the lipophilic group of the glycerin fatty acid ester associate with each other to form stable micelles. The fatty acid of the polyglycerin fatty acid ester is preferably selected from the group consisting of oleic acid, linoleic acid, linolenic acid, and mixtures thereof. Also, the polyglycerin may be diglycerol, triglycerol, tetraglycerol, pentaglycerol, hexaglycerol, decaglycerol and mixtures thereof.
이렇게 제조된 마이셀 유화 토코페롤 조성물은 산화안정성이 확보되어 장기 저장이 가능하고, 분산성이 증대되어 식품에 첨가 시 다른 성분과의 혼합이 용이하며, 섭취 시 체내에서 보다 잘 분산되어 매우 유용하게 사용될 수 있을 것으로 기대된다.The micellar emulsifying tocopherol composition thus prepared can be stored for a long period of time by ensuring its oxidation stability and its dispersibility is increased. When it is added to foods, it can be easily mixed with other components and dispersed more effectively in the body when consumed. It is expected to be.
본 발명의 마이셀 유화 토코페롤 조성물은 식품, 화장품 또는 사료에 사용될 수 있다.The micellar emulsified tocopherol composition of the present invention can be used in foods, cosmetics or feed.
이하에서는 구체적인 실시예를 통하여 본 발명을 더욱 상세하게 설명한다. 하기 실시에는 본 발명의 바람직한 일 구체예를 기재한 것이며, 하기 실시예의 기재 사항에 의하여 본 발명의 권리범위가 한정되는 것은 아님은 명백하다.Hereinafter, the present invention will be described in more detail with reference to specific examples. The following examples are illustrative of preferred embodiments of the present invention, and it is apparent that the scope of the present invention is not limited by the description of the following examples.
[실시예][Example]
실시예Example
혼합토코페롤 96%를 함유하는 디-알파 토코페롤 2,250g(상품명: d-alpha-Tocopherol DSM), 중쇄지방산을 함유하는 유지 2,250g(상품명: Radia 7104), 올레인산을 82중량% 함유하는 글리세린지방산에스테르 150g(상품명: Excel O-95R KAO Corporation)을 35℃에서 혼합한 다음, 질소를 투입하면서 10분간 3,000rpm으로 호모믹싱하였다. 호모믹싱한 혼합물을 고압호모게나이저에 2회 통과시킨 후 폴리글리세린지방산에스테르 350g(상품명: DS-100A Riken Vitamin)을 첨가하여 5분간 호모믹싱 후 25℃로 냉각시켜 토코페롤을 함유하는 마이셀 유화 조성물를 제조하였다.2,250 g (trade name: d-alpha-Tocopherol DSM) of di-alpha tocopherol containing 96% of mixed tocopherol, 2,250 g (trade name: Radia 7104) of a fat containing medium chain fatty acid, 150 g of glycerin fatty acid ester containing 82% (Trade name: Excel O-95R KAO Corporation) was mixed at 35 DEG C and then homomixed at 3,000 rpm for 10 minutes while nitrogen was supplied. After the homomixed mixture was passed twice through a high-pressure homogenizer, 350 g of polyglycerol fatty acid ester (trade name: DS-100A Riken Vitamin) was added and homomixed for 5 minutes and then cooled to 25 캜 to prepare a micelle emulsion composition containing tocopherol Respectively.
비교예Comparative Example
혼합토코페롤 96%를 함유하는 디-알파 토코페롤 2,250g과 레시틴 100g(상품명: SOLEC® Soy Lecithin DANISCO)을 40℃에서 혼합하여 준비하고, 솔비톨 2,400g(상품명: D-소르비톨액 ㈜엘지생활건강)과 폴리글리세린지방산에스테르 250g(상품명: PO-100 Riken Vitamin)을 40℃에서 혼합하여 유화 준비한다. 질소를 투입하면서 솔비톨에 혼합토코페롤을 서서히 첨가하여 20분간 호모믹싱 후 고압호모게나이저에 통과하여 유화물을 제조하였다.Di-containing mixed tocopherols 96% alpha tocopherol and lecithin 2,250g 100g (trade name: SOLEC ® Soy Lecithin DANISCO) preparing a mixture at 40 ℃, and 2,400g sorbitol (trade name: D- sorbitol solution ㈜ LG Household & Health Care) and 250 g of polyglycerin fatty acid ester (trade name: PO-100 Riken Vitamin) was mixed at 40 캜 and emulsified. Mixed tocopherol was gradually added to sorbitol while nitrogen was added, homomixed for 20 minutes, and then passed through a high pressure homogenizer to prepare an emulsion.
실험예Experimental Example
산화안정성 측정Oxidation stability measurement
산화안정성은 130℃, 20ℓ/min 통기량 조건에서 메트롬743랜시맷(Metrohm 743 Rancimat)를 사용하여 산화 유도기간(induction time)을 측정하였다. Oxidative stability was measured by induction time using Metrom 743 Rancimat at 130 ° C and 20 L / min aeration.
상기 표 1에 나타난 바와 같이, 본 발명의 실시예의 조성물은 비교예의 조성물보다 산화유도기간이 길어 산화안정성이 높음을 확인하였다.As shown in Table 1, the compositions of the examples of the present invention were confirmed to have high oxidation stability because the oxidation induction period was longer than that of the comparative examples.
항산화 효능의 측정Measurement of Antioxidant Efficacy
안정한 자유 라디칼인 DPPH를 이용하여 라디칼이 감소하는 정도를 분광광도계로 측정하여 간접적으로 시료의 항산화 활성을 측정하였다.The antioxidative activity of the sample was measured indirectly by measuring the degree of reduction of radicals using a stable free radical, DPPH, using a spectrophotometer.
(천연 토코페롤 45% 함유)Example
(Containing 45% natural tocopherol)
(천연 토코페롤 45% 함유)Comparative Example
(Containing 45% natural tocopherol)
상기 표 2에 나타난 바와 같이, 본 발명의 실시예의 조성물은 천연 토코페롤이 갖는 항산화 활성을 감소시키지 않음을 확인하였으며, 비교예의 경우 항산화 활성이 크게 감소함을 확인하였다.As shown in Table 2, it was confirmed that the composition of the present invention did not decrease the antioxidative activity of natural tocopherol, and the antioxidative activity of the comparative example was greatly reduced.
터비스캔을 이용한 유화안정성 실험Emulsion stability experiment using the Turb scan
유화물의 안정성을 측정하는 데에 사용하는 터비스캔(Turbiscan)을 사용하여 실시예와 비교예로 제조된 유화물의 유화안정성을 측정하였다. The emulsion stability of the emulsions prepared in Examples and Comparative Examples was measured using Turbiscan, which is used to measure the stability of emulsions.
실험조건 : 온도 55℃, 기간 6일Experimental conditions: temperature 55 ° C, duration 6 days
도 1 및 도 2에 나타난 바와 같이, 본 발명의 방법에 따라 제조된 실시예의 마이셀 구조 조성물이 안정성 시험에서 비교예에 비해 크림밍(creaming), 침전(sedimentation) 및 합일(flocculation, coalescence)에서 뛰어난 안정성을 보였다.As shown in FIGS. 1 and 2, the micelle structure compositions of the examples prepared according to the method of the present invention are excellent in creaming, sedimentation and flocculation (coalescence) Stability.
Claims (8)
(b) 중쇄 지방산을 함유하는 유지 10 내지 99 중량부;
(c) 글리세린지방산에스테르 1 내지 20 중량부; 및
(d) 폴리글리세린지방산에스테르 1 내지 30 중량부를 포함하는 마이셀 유화 토코페롤 조성물.(a) 1 to 90 parts by weight of natural tocopherol;
(b) 10 to 99 parts by weight of a fat-containing fatty acid chain;
(c) 1 to 20 parts by weight of a glycerin fatty acid ester; And
(d) 1 to 30 parts by weight of a polyglycerol fatty acid ester.
상기 천연토코페롤은 알파-, 베타-, 감마- 및 델타-토코페롤로 이루어지는 군으로부터 선택되는 것을 특징으로 하는 마이셀 유화 토코페롤 조성물.The method according to claim 1,
Wherein said natural tocopherol is selected from the group consisting of alpha-, beta-, gamma- and delta-tocopherol.
상기 중쇄 지방산은 카프릴산, 카프릭산 및 이들의 혼합물을 90중량% 이상 포함하는 것을 특징으로 하는 마이셀 유화 토코페롤 조성물.The method according to claim 1,
Wherein the heavy chain fatty acid comprises at least 90% by weight of caprylic acid, capric acid and mixtures thereof.
상기 글리세린지방산에스테르 및 폴리글리세린지방산에스테르를 구성하는 지방산은 올레인산, 리놀산, 리놀렌산 및 이들의 혼합물로 이루어지는 군으로부터 선택되는 것을 특징으로 하는 마이셀 유화 토코페롤 조성물.The method according to claim 1,
Wherein the fatty acid constituting the glycerin fatty acid ester and the polyglycerin fatty acid ester is selected from the group consisting of oleic acid, linoleic acid, linolenic acid, and mixtures thereof.
상기 폴리글리세린지방산에스테르를 구성하는 폴리글리세린은 디글리세린, 트리글리세린, 테트라글리세린, 펜타글리세린, 헥사글리세린, 데카글리세린 및 이들의 혼합물로 이루어지는 군으로부터 선택되는 것을 특징으로 하는 마이셀 유화 토코페롤 조성물.The method according to claim 1,
Wherein the polyglycerin constituting the polyglycerin fatty acid ester is selected from the group consisting of diglycerin, triglycerin, tetraglycerin, pentaglycerin, hexaglycerin, decaglycerin, and mixtures thereof.
상기 마이셀의 직경은 0.1~500μm인 것을 특징으로 하는 마이셀 유화 토코페롤 조성물. 6. The method according to any one of claims 1 to 5,
Wherein the micelle has a diameter of 0.1 to 500 탆.
(2) 상기 단계 (1)에서 호모믹싱된 혼합물을 초고압호모게나이져에 통과시키는 단계; 및
(3) 상기 단계 (2)에서 초고압호모게나이져에 통과된 혼합물에 폴리글리세린지방산에스테르 1 내지 30 중량부를 첨가하여 혼합하고, 3 내지 5분 동안 호모믹싱 후 30℃ 이하로 냉각시키는 단계를 포함하는 마이셀 유화 토코페롤 조성물의 제조방법.(1) 10 to 90 parts by weight of (a) 10 to 90 parts by weight of natural tocopherol, (b) 10 to 90 parts by weight of a fat-containing fatty acid chain, (c) 1 to 20 parts by weight of a glycerin fatty acid ester, Homomixing at 2,000 to 3,000 rpm for 5 to 10 minutes while feeding;
(2) passing the homomixed mixture through an ultrahigh pressure homogenizer in step (1); And
(3) adding 1 to 30 parts by weight of a polyglycerol fatty acid ester to the mixture passed through the ultra-high pressure homogenizer in the step (2), mixing and homogenizing for 3 to 5 minutes and then cooling to 30 DEG C or less A process for preparing a micelle-emulsifying tocopherol composition.
상기 조성물은 식품, 화장품 또는 사료에 사용하는 것을 특징으로 하는 마이셀 유화 토코페롤 조성물.The method according to claim 6,
Wherein the composition is used in foods, cosmetics or feeds.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020160136774A KR20180043699A (en) | 2016-10-20 | 2016-10-20 | Mischell emulsionized tocopherol composition and manufacturing method thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020160136774A KR20180043699A (en) | 2016-10-20 | 2016-10-20 | Mischell emulsionized tocopherol composition and manufacturing method thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
KR20180043699A true KR20180043699A (en) | 2018-04-30 |
Family
ID=62080949
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020160136774A KR20180043699A (en) | 2016-10-20 | 2016-10-20 | Mischell emulsionized tocopherol composition and manufacturing method thereof |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR20180043699A (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022131653A1 (en) * | 2020-12-15 | 2022-06-23 | 윤관식 | Water-soluble emulsion composition containing natural polyphenol compound |
-
2016
- 2016-10-20 KR KR1020160136774A patent/KR20180043699A/en active Search and Examination
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022131653A1 (en) * | 2020-12-15 | 2022-06-23 | 윤관식 | Water-soluble emulsion composition containing natural polyphenol compound |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP3103430B2 (en) | Fat-soluble antioxidant mixture | |
Pan et al. | Xanthan gum-assisted fabrication of stable emulsion-based oleogel structured with gelatin and proanthocyanidins | |
JP6814148B2 (en) | Emulsion for parenteral administration | |
JP6027749B2 (en) | Oil-soluble antioxidant and method for producing the same | |
KR20140040754A (en) | Astaxanthin-containing composition, method for manufacturing same, and cosmetic | |
JP2020508695A (en) | Stable fat-soluble active ingredient composition, microcapsule and method for producing the same and application | |
US20080207777A1 (en) | Emulsifier System, Emulsion and the Use Thereof | |
TW201733448A (en) | Fat or oil composition exhibiting anti-oxidation properties | |
JP4910927B2 (en) | Astaxanthin-containing emulsion and production method | |
JP2007326829A (en) | Emulsion composition | |
JP6964660B2 (en) | Antioxidant dispersion | |
EP1679063B1 (en) | Novel liquid preparation composition | |
JP6005018B2 (en) | Cosmetic and emulsified composition containing glycyrrhetinic acid derivative | |
KR20180043699A (en) | Mischell emulsionized tocopherol composition and manufacturing method thereof | |
EP3520620A1 (en) | Premix for preparing emulsion composition, and composition using same | |
JP2006129841A (en) | alpha-LIPOIC ACID-CONTAINING AQUEOUS COMPOSITION | |
JP6622950B1 (en) | Compositions for preparing microemulsions, microemulsions, methods for their production and use of microemulsions | |
US20050209315A1 (en) | Bioavailable nutritional supplement and method of treatment of malabsorption | |
JP6667043B1 (en) | Microemulsions and the use of microemulsions | |
KR20220122840A (en) | Water-soluble emulsion composition comprising alkaloids | |
KR100876308B1 (en) | Manufacturing method of water-soluble tocopherol emulsion | |
WO2016129611A1 (en) | Antioxidant composition and oil having same added thereto | |
CA3117475A1 (en) | Oral composition containing reduced coenzyme q10, method for producing same, method for preventing discoloration and discoloration preventing agent | |
JPH10212477A (en) | Prevention of oxidation of o/w type emulsion, antioxidant composition and w/o type emulsion | |
RU2514414C1 (en) | Antioxidant premix and its production method |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
A302 | Request for accelerated examination | ||
E902 | Notification of reason for refusal | ||
AMND | Amendment | ||
E601 | Decision to refuse application | ||
AMND | Amendment | ||
J201 | Request for trial against refusal decision | ||
J301 | Trial decision |
Free format text: TRIAL NUMBER: 2017101002809; TRIAL DECISION FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20170609 Effective date: 20181023 |